ROCKVILLE, Md., Sept. 26,
2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX)
today announced presentations at the 28th Annual
Congress of the World Muscle Society, taking place in Charleston, SC from October 3-7, 2023. Presentations include interim
data from the Phase I/II AFFINITY DUCHENNE™ trial, including
longer-term safety and initial microdystrophin protein expression
levels in muscle at three months.
The presentations will be presented as follows:
Abstract Title: An investigational AAV8 gene therapy
coding for a novel microdystrophin as a treatment for Duchenne
muscular dystrophy (P16)
Presenter: Jahannaz Dastgir, DO, Senior Director,
Clinical Development, REGENXBIO
Abstract Title: RGX-202, an investigational gene therapy
for the treatment of Duchenne muscular dystrophy: interim clinical
data (LBP19)
Presenter: Aravindhan Veerapandiyan,
M.D., Arkansas Children's Hospital
REGENXBIO will host a conference call on Tuesday, October 3, 2023 starting at 4:30 PM ET to review the interim data being
presented in greater detail. Instructions for joining the call will
be available in the data release and on the Investors section
of REGENXBIO's website at www.regenxbio.com.
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company
seeking to improve lives through the curative potential of gene
therapy. REGENXBIO's NAV Technology Platform, a proprietary
adeno-associated virus (AAV) gene delivery platform, consists of
exclusive rights to more than 100 novel AAV vectors, including
AAV7, AAV8 and AAV9. REGENXBIO and its third-party NAV Technology
Platform Licensees are applying the NAV Technology Platform in the
development of a broad pipeline of candidates, including late-stage
and commercial programs, in multiple therapeutic areas. REGENXBIO
is committed to a "5x'25" strategy to progress five AAV
Therapeutics from our internal pipeline and licensed programs into
pivotal-stage or commercial products by 2025.
Contacts:
Dana Cormack
Corporate
Communications
dcormack@regenxbio.com
Investors:
Chris Brinzey
ICR Westwicke
339-970-2843
chris.brinzey@westwicke.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/regenxbio-announces-presentations-at-the-28th-annual-congress-of-the-world-muscle-society-301938357.html
SOURCE REGENXBIO Inc.